2022 Financial Times Global Pharma and Biotech Summit
Driving Investment and Innovation in Life Sciences
Join Deloitte at
2022 Financial Times Global Pharma and Biotech Summit, an industry-leading conference which brings together the world’s biggest pharma companies and other major organizations across the life sciences and health care value chain. The annual event is essential for you to stay on top of the latest trends and innovations in life sciences. CEOs, policymakers and thought leaders from around the world will explore new frontiers for business and for health care and discuss what’s new in areas such as drug discovery, clinical trials and market access.
While the life sciences and health care industry is witnessing a technological innovation since the pandemic, how is the competition between pharma companies and institutional investors for biotech platforms evolving? The industry is already transforming the clinical trial landscape and leveraging health care intelligence, but is scientific complexity still a hurdle? At the same time, the role of companies’ ethics, sustainability and customer value factors could be at the heart of any responsible business strategy. Deloitte leaders, along with industry peers, will unpack many of these critical questions and more at this year’s conference.
Deloitte is proud to once again be a lead sponsor and is pleased to offer a discounted registration to this year’s conference.
Register now to receive a 25% discount
Showing Leadership: What does a good workforce transformation strategy look like? How do pharma companies set ESG goals? How do CEOs make the big calls on where to focus investment?
Supporting Innovation: Will cross-industry collaboration continue beyond the pandemic? How is technology transforming R&D? What are the latest next-generation therapies?
Saving Lives: What does the rise of precision medicine look like? How can pharma companies become more patient-centric? How can high-cost treatments be made more accessible and affordable?
Partnerships—Driving innovation through collaboration
What are the emerging opportunities for stakeholders to build partnerships and how do we predict the shift in balance of in-house and outsourced R&D?
David Loew, CEO, Ipsen
Ger Brophy, Executive Vice President, Biopharma Production, Avantor
John Haughey, Global Life Sciences & Health Care Consulting Leader, Deloitte
Kate Bingham, Managing Partner, SV Health Investors
Nerida Scott, Head of J&J Innovation EMEA, Johnson & Johnson
Moderator: Clive Cookson, Science Editor, Financial Times
Digital Transformation in Life Sciences
Translating social determinants of health to business models
What is the case for using data on social determinants of health across different stages of the pharma-biotech value chain, from drug development to patient access?
Lu Zheng, Head EUCAN Value Based Partnerships and Patient Services, Takeda
Marie- Andrée Gamache, Country President, Novartis UK and Ireland
Laura Steele, President and General Manager, Lilly UK, Ireland, and Northern Europe Hub, Eli Lilly
Moderator: Greg Reh, Global Life Sciences and Health Care Industry Leader, Deloitte
Strengthening health ecosystems
Drug discovery—Applying data science in early-stage R&D
What is the potential for AI to predict drug behavior and how are cloud-based solutions being plugged into discovery models?
Reza Sadeghi, Chief Strategy Officer, BIOVIA, Dassault Systemes
Werngard Czechtizky, Head of Medicinal Chemistry, Respiratory and Immunology, Chair of AZ Global Chemistry Leadership, AstraZeneca
Moderator: Laveshni Reddy, Director, Life Sciences and Health Care Practice, Deloitte
Frank Nestle, Global Head of Research and Chief Scientific Officer, Sanofi
Moderator: Naveed Panjwani, Director, Life Sciences and Health Care Practice, Deloitte UK
Life Sciences R&D Insights
Drug development—Digitizing, decentralizing and accelerating R&D
What are the various drug development strategies and what are some of the challenges in ensuring the integrity of decentralized clinical trials?
Colin Terry, Partner, Life Sciences Consulting Leader, Deloitte
Harpreet Gill, Head of Decentralized Clinical Trial Solutions, ICON plc
Kim McLean Boericke, Chief Delivery Officer, THREAD
·Fareed Melhem, SVP,
Moderator: Hannah Kuchler, Global Pharmaceuticals Correspondent, Financial Times
Measuring the return from pharmaceutical innovation 2021
Pricing and market access—What to expect in 2023
What are the most likely developments in pricing and market access for high-cost advanced therapies and what can be done to increase access and affordability in emerging markets?
Jayasree K. Iyer, CEO, Access to Medicine Foundation
Richard Saynor, CEO, Sandoz
Ana Plata, Global Pricing Head, BioPharmaceuticals, AstraZeneca Richard Torbett, Chief Executive, Association of the British Pharmaceutical Industry
Moderator: Vicky Levy, Global Life Sciences Sector Leader, Deloitte
Pharma market access and launch strategies
Operating models—How can pharma companies be more agile and less fragile?
How can agile principles be applied in different parts of the pharma value chain and how should ESG goals be integrated into operating models?
Ian Thompson, Senior Vice President, US Business Operations, Amgen
Estelle Vester-Blokland, Senior Vice President, Global Medical Affairs, Bristol Myers Squibb
Róbert Wessman, Chairman and CEO, Alvogen
Moderator: James Gregson, Life Sciences & Health Care Industry Leader, Deloitte UK
Climate change and health care